Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol
This article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2014-09-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29049/pdf |
| _version_ | 1819228813132824576 |
|---|---|
| author | G A Baryshnikov I I Stepanova N A Kudryavtseva |
| author_facet | G A Baryshnikov I I Stepanova N A Kudryavtseva |
| author_sort | G A Baryshnikov |
| collection | DOAJ |
| description | This article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokinetic characteristics of metoprolol succinate retard with other beta-adrenoreceptor-blocking agents showed metoprolol succinate advantage over the short-term drugs for treatment of CHF. According to the results of randomised clinical trialswe determined high therapeutic efficacy and safety of metoprolol succinate retard. |
| first_indexed | 2024-12-23T11:03:14Z |
| format | Article |
| id | doaj.art-9c67b74ab66b4584ac38b7372a08659a |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-12-23T11:03:14Z |
| publishDate | 2014-09-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-9c67b74ab66b4584ac38b7372a08659a2022-12-21T17:49:34ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892014-09-01113687426150Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprololG A BaryshnikovI I StepanovaN A KudryavtsevaThis article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokinetic characteristics of metoprolol succinate retard with other beta-adrenoreceptor-blocking agents showed metoprolol succinate advantage over the short-term drugs for treatment of CHF. According to the results of randomised clinical trialswe determined high therapeutic efficacy and safety of metoprolol succinate retard.https://syst-hypertension.ru/2075-082X/article/viewFile/29049/pdfbeta-adrenergic blocking agentmetoprololsuccinateischemic heart diseasechronic cardiac failurearterial hypertension |
| spellingShingle | G A Baryshnikov I I Stepanova N A Kudryavtseva Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol Системные гипертензии beta-adrenergic blocking agent metoprololsuccinate ischemic heart disease chronic cardiac failure arterial hypertension |
| title | Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol |
| title_full | Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol |
| title_fullStr | Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol |
| title_full_unstemmed | Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol |
| title_short | Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol |
| title_sort | beta adrenergic blocking agent in cardiovascular disease focus on metoprolol |
| topic | beta-adrenergic blocking agent metoprololsuccinate ischemic heart disease chronic cardiac failure arterial hypertension |
| url | https://syst-hypertension.ru/2075-082X/article/viewFile/29049/pdf |
| work_keys_str_mv | AT gabaryshnikov betaadrenergicblockingagentincardiovasculardiseasefocusonmetoprolol AT iistepanova betaadrenergicblockingagentincardiovasculardiseasefocusonmetoprolol AT nakudryavtseva betaadrenergicblockingagentincardiovasculardiseasefocusonmetoprolol |